Hjem › Crohns sygdom › New York

Crohns sygdom kliniske forsøg i New York

36 studier for Crohns sygdom søger deltagere på steder i New York.

Byer i New York

Officiel studietekst (engelsk)

Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)

New York Gastroenterology Associates ( Site 0253), New York

RekruttererFase 3

Alle aldre · Alle køn · Opdateret 2. okt. 2026 · NCT06651281

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

Northwell Health Physician Partners Center for Advanced IBD Care ( Site 5017), Great Neck
NYU Langone Health - Inflammatory Bowel Disease Center (IBD) ( Site 5078), New York
Weill Cornell Medical College, New-York Presbyterian Hospital ( Site 5079), New York
og 2 flere

RekruttererFase 3

Alder 16 til 80 · Alle køn · Opdateret 2. okt. 2026 · NCT06430801

Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

New York Gastroenterology Associates - Upper East Side /ID# 281767, New York

RekruttererFase 2

Alder 18 til 75 · Alle køn · Opdateret 2. okt. 2026 · NCT07697456

A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting

Westchester Putnam Gastroenterology PC, Carmel
Five Towns Gastroenterology, Cedarhurst
IMIDeology, Elmhurst
og 5 flere

RekruttererFase 4

Alder 18 til 80 · Alle køn · Opdateret 30. sep. 2026 · NCT06581328

A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

Weill Cornell Medical College - Judith Jaffe Multiple Sclerosis Center, New York
Icahn School of Medicine at Mount Sinai, New York

RekruttererFase 3

Alder 2 til 17 · Alle køn · Opdateret 25. sep. 2026 · NCT05923073

Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

Nyu Langone Long Island Clinical Research Associates - Lake Success /ID# 265566, Lake Success
Northwell Health-Lenox Hill Hospital /ID# 265527, New York
Care Access - Yonkers /ID# 266781, Yonkers

RekruttererFase 2

Alder 18 til 75 · Alle køn · Opdateret 25. sep. 2026 · NCT06548542

A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

Westchester Putnam Gastroenterology, Carmel
New York Gastroenterology Associates, New York

RekruttererFase 3

Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT07499232

A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

Westchester Putnam Gastroenterology, Carmel
Inflammatory Bowel Disease Center at NYU Langone, New York
Weill Cornell Medical College, New York
og 2 flere

RekruttererFase 2/3

Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT07196722

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Icahn School of Medicine at Mount Sinai (ISMMS) - The Mount Sinai Hospital (MSH), New York
Rochester Clinical Research, Inc, Rochester

RekruttererFase 2

Alder 18 til 75 · Alle køn · Opdateret 25. sep. 2026 · NCT06233461

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

New York Gastroenterology Associates, New York
Care Access - Yonkers, Yonkers

RekruttererFase 3

Alder 18 til 70 · Alle køn · Opdateret 24. sep. 2026 · NCT06937099

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

NYU Langone Hospital - Long Island, Mineola
Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
og 1 flere

RekruttererFase 1

Alder 18 og opefter · Alle køn · Opdateret 23. sep. 2026 · NCT03816345

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

MedTraits NY-Site Number: 8400045, Maspeth
Manhattan Clinical Research, LLC-Site Number: 8400069, New York
NYU Langone Health-Site Number: 8400091, New York
og 4 flere

RekruttererFase 3

Alder 16 til 80 · Alle køn · Opdateret 23. sep. 2026 · NCT07184931

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

MedTraits NY-Site Number: 8400045, Maspeth
NYU Langone Health-Site Number: 8400091, New York
Weill Cornell Medicine - NewYork-Presbyterian Hospital-Site Number: 8400040, New York
og 1 flere

RekruttererFase 3

Alder 16 til 80 · Alle køn · Opdateret 23. sep. 2026 · NCT07184944

A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

Icahn School of Medicine at Mount Sinai /ID# 254880, New York

RekruttererFase 3

Alder 2 til 17 · Alle køn · Opdateret 23. sep. 2026 · NCT05995353

A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

Icahn School of Medicine at Mount Sinai, New York

RekruttererFase 3

Alder 2 til 19 · Alle køn · Opdateret 22. sep. 2026 · NCT04844606

A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

NYU Langone Health, New York

RekruttererFase 4

Alder 18 til 70 · Alle køn · Opdateret 9. sep. 2026 · NCT06045754

Standardized Microbiota Transplant Therapy in Crohn's Disease

NYU Langone Health, New York

RekruttererFase 2

Alder 18 til 89 · Alle køn · Opdateret 8. sep. 2026 · NCT06631586

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

New York Gastroenterology Associates, New York

RekruttererFase 3

Alder 18 og opefter · Alle køn · Opdateret 28. aug. 2026 · NCT07577843

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

Weill Cornell Medical College (WCMC) - Judith Jaffe Multiple Sclerosis Center (JJMSC), New York
Icahn School of Medicine at Mount Sinai, New York
Columbia University Medical Center/New York Presbyterian, New York

RekruttererFase 3

Alder 2 til 17 · Alle køn · Opdateret 24. aug. 2026 · NCT05509777